Abstract:The author requested to add a co-author after the publication of the original article [1]. In this correction, the author has been added in the article entitled "GSK-3 Inhibitors in the Regulation and Control of Colon Carcinoma" in the journal "Current Drug Targets" 2021; 22(13), 1485-1495. Details of the error and a correction are provided here. The original editorial can be found online at 10.2174/1389450122666210204203950 We regret any errors and apologize to the readers. Original: Sitansu S. Nanda1, Md Imran Hossain1, Heongkyu Ju2 and Dong Kee Yi1,* 1Department of Chemistry, Myongji University, Yongin, 03674, South Korea; 2Department of Physics, Gachon University, Seongnam-si, Gyeonggi-do, South Korea Corrected: Sitansu S. Nanda1, Md Imran Hossain1, Heongkyu Ju2, Georgia C. Papaefthymiou3 and Dong Kee Yi1,* 1Department of Chemistry, Myongji University, Yongin, 03674, South Korea; 2Department of Physics, Gachon University, Seongnam-si, Gyeonggi-do, South Korea 3Department of Physics, Villanova University, Villanova, Pennsylvania19085, USA.

Erratum to: A novel GSH responsive poly(alpha-lipoic acid) nanocarrier bonding with the honokiol-DMXAA conjugate for combination therapy

Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Correction: Corrigendum: Autophagy-associated alpha-arrestin signaling is required for conidiogenous cell development in Magnaporthe oryzae

Corrigendum to: Progress of Angiogenesis Signal Pathway and Antiangiogenic Drugs in Nasopharyngeal Carcinoma

Corrigendum to “the Induction of Reactive Oxygen Species and Loss of Mitochondrial Omi/HtrA2 is Associated with S-nitrosoglutathione-induced Apoptosis in Human Endothelial Cells” [toxicology and Applied Pharmacology 244 (2010) 374–384]

Erratum: Author correction to 'Co-delivery of nigericin and decitabine using hexahistidine-metal nanocarriers for pyroptosis-induced immunotherapeutics' [Acta Pharm Sin B 12 (2022) 4458-4471]

Erratum to “Near-infrared responsive 5-fluorouracil and indocyanine green loaded MPEG-PCL nanoparticle integrated with dissolvable microneedle for skin cancer therapy” [Bioact. Mater. 5 (2020) 542–552]

Corrigendum to "Emulsifying Lipiodol with pH-Sensitive DOX@HmA nanoparticles for hepatocellular carcinoma TACE treatment eliminate metastasis" Mater. Today Bio, 23, 2023, 100873, ISSN 2590-0064

Corrigendum to"Synergistically targeting synovium STING pathway for rheumatoid arthritis treatment" [Bioact Mater 24 (2022) 37-53]

Corrigendum to: Investigation of the Apoptosis Inducing and β-catenin Silencing by Tetradentate Schiff Base Zinc(II) Complex on the T-47D Breast Cancer Cells

Tumor Theranostics of Transition Metal Ions Loaded Polyaminopyrrole Nanoparticles: Erratum

Erratum: Author Correction to "Tumor-Microenvironment Activated Duplex Genome-Editing Nanoprodrug for Sensitized Near-Infrared Titania Phototherapy" [acta Pharm Sin B (2022) 4224-4234].

Correction: Ma et al. Hyaluronic Acid Modified Nanostructured Lipid Carrier for Targeting Delivery of Kaempferol to NSCLC: Preparation, Optimization, Characterization, and Performance Evaluation In Vitro. Molecules 2022, 27, 4553

Nanosonosensitizers for Highly Efficient Sonodynamic Cancer Theranostics: Erratum

Erratum: Author correction to 'Real-time SERS monitoring anticancer drug release along with SERS/MR imaging for pH-sensitive chemo-phototherapy' [Acta Pharm Sin B 13 (2023) 1303-1317]

Erratum to: Multifunctional peptide conjugated amphiphilic cationic copolymer for enhancing ECs targeting, penetrating and nuclear accumulation

Correction: LAPONITE® Nanodisk-Based Platforms for Cancer Diagnosis and Therapy

Corrigendum to: GSK-3 Inhibitors in the Regulation and Control of Colon Carcinoma

Author correction to “Coordinated regulation of BACH1 and mitochondrial metabolism through tumor targeted self-assembled nanoparticles for effective triple negative breast cancer combination therapy” [Acta Pharmaceutica Sinica B 12 (2022) 3934–3951]